Abivax Reports Q1 2026 Financial Results with Extended Cash Runway

Abivax (NASDAQ:ABVX) reported its first-quarter financial results for 2026, revealing a cash position of €491.6 million that is expected to last through the fourth quarter of 2027. The company noted increased R&D expenses due to ongoing trials and promising three-year interim data from Study 108 on obefazimod in ulcerative colitis patients.

By Maham Fatima Wed, June 17, 2026 at 9:28 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 18:28 UTC

Tickers: $ABVX

Topics: biotech cash_runway clinical_trials

Read the full article at Yahoo Finance

More World news

Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC